Ann: CLINUVEL expands Singapore laboratory facilities, page-6

Clinuvel have never had trouble raising cash. Getting cash to run trials to develop the company is sort of what the stock market is for. Also running a phase 1 trial for a topical emulsion to see if it works would cost much less than a Wolgren loyalty bonus. The reason I expect that no progress has been made in 8 years with CUV9900 is the singular focus on FDA approval. Whether Clinuvel can walk and chew gum at the same time is yet to be proven, whether the singular focus on FDA approval is the right option is also yet to be proven. It is going to look a bit silly if CUV9900 is a blockbuster and was held back 8 years just because it didn't fit into the long term corporate strategy. Only time will tell.